BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND FLT3, STK1, 2322, ENSG00000122025, P36888, FLK2, CD135, RP11-153M24_3 AND Treatment
26078 results:

  • 1. Impact of Fee For Service on the Efficiency and Survival of Seguro Popular's Patients With Acute Lymphoblastic leukemia in Mexico.
    Cerecero-García D; Macías-González F; Muñoz-Aguirre P; Huerta-Gutierrez R; Zapata M; Rivera-Luna R; Lajous M; Bautista-Arredondo S
    JCO Glob Oncol; 2024 May; 10():e2300060. PubMed ID: 38754053
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Pharmacogenomics, Race, and treatment Outcome in Pediatric Acute Myeloid leukemia.
    Lamba JK; Marrero R; Wu H; Cao X; Parcha PK; Karol SE; Inaba H; Kuo DJ; Degar BA; Heym K; Taub JW; Lacayo NJ; Pui CH; Ribeiro RC; Pounds SB; Rubnitz JE
    JAMA Netw Open; 2024 May; 7(5):e2411726. PubMed ID: 38753328
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. The efficacy of the combination of venetoclax and hypomethylating agents versus HAG agents in patients with acute myeloid leukemia: a retrospective study.
    Xin F; Yu YH; Shen XL; Zhang GX
    Hematology; 2024 Dec; 29(1):2350319. PubMed ID: 38748459
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Real-world data on diagnostics, treatment and outcomes of patients with hairy cell leukemia: The HCL-CLLEAR study.
    Panovská A; Žák P; Jurková T; Arpáš T; Brychtová Y; Vašíková A; Hrabčáková V; Prchlíková A; Filipová M; Doubek M
    Hematol Oncol; 2024 May; 42(3):e3280. PubMed ID: 38741354
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Therapeutic Choices in Patients with Ph-Positive Chronic Myelogenous leukemia In Mexico in the Era of Tyrosine Kinase Inhibitors: Stem Cell Transplantation or Tyrosine Kinase Inhibitors? Fifteen Years Later.
    Max RN; Daniela SB; Moisés M GP; Edgar J HF; Merittzel A MR; María de L PM; Juan C OG; Guillermo J RD; Guillermo J RA
    Rev Invest Clin; 2024; 76(2):91-96. PubMed ID: 38740380
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Valrubicin-loaded immunoliposomes for specific vesicle-mediated cell death in the treatment of hematological cancers.
    Georgievski A; Bellaye PS; Tournier B; Choubley H; Pais de Barros JP; Herbst M; Béduneau A; Callier P; Collin B; Végran F; Ballerini P; Garrido C; Quéré R
    Cell Death Dis; 2024 May; 15(5):328. PubMed ID: 38734740
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. (2,6-Dimethylphenyl)arsonic Acid Induces Apoptosis through the Mitochondrial Pathway, Downregulates XIAP, and Overcomes Multidrug Resistance to Cytostatic Drugs in leukemia and Lymphoma Cells In Vitro.
    Wilke N; Frias C; Berkessel A; Prokop A
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731935
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Systems Biology for Drug Target Discovery in Acute Myeloid leukemia.
    Novikova S; Tolstova T; Kurbatov L; Farafonova T; Tikhonova O; Soloveva N; Rusanov A; Zgoda V
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731835
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Efficacy of surgical treatment of perianal infection in patients with hematological malignancy.
    He J; Ni Z; Li Z
    Medicine (Baltimore); 2024 May; 103(19):e38082. PubMed ID: 38728504
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Personalized Timing for Allogeneic Stem-Cell Transplantation in Hematologic Neoplasms: A Target Trial Emulation Approach Using Multistate Modeling and Microsimulation.
    Gregorio C; Spreafico M; D'Amico S; Sauta E; Asti G; Lanino L; Tentori CA; Platzbecker U; Haferlach T; Diez-Campelo M; Fenaux P; Komrokji R; Della Porta MG; Ieva F
    JCO Clin Cancer Inform; 2024 May; 8():e2300205. PubMed ID: 38723213
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
    Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
    [No Abstract]    [Full Text] [Related]  

  • 12. [Efficacy of allogeneic hematopoietic stem cell transplantation based on a total body irradiation conditioning treatment regimen for adult acute lymphocytic leukemia].
    Xiao QQ; Yu XL; Song XC; Hou YX; Deng L; Li WJ; Zhou F
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):249-256. PubMed ID: 38716596
    [No Abstract]    [Full Text] [Related]  

  • 13. [treatment status of tyrosine kinase inhibitor for newly-diagnosed chronic myeloid leukemia: a domestic multi-centre retrospective real-world study].
    Zhang XS; Liu BC; Du X; Zhang YL; Xu N; Liu XL; Li WM; Lin H; Liang R; Chen CY; Huang J; Yang YF; Zhu HL; Pan L; Wang XD; Li GH; Liu ZG; Zhang YQ; Liu ZF; Hu JD; Liu CS; Li F; Yang W; Meng L; Han YQ; Lin LE; Zhao ZY; Tu CQ; Zheng CF; Bai YL; Zhou ZP; Chen SN; Qiu HY; Yang LJ; Sun XL; Sun H; Zhou L; Liu ZL; Wang DY; Guo JX; Pang LP; Zeng QS; Suo XH; Zhang WH; Zheng YJ; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):215-224. PubMed ID: 38716592
    [No Abstract]    [Full Text] [Related]  

  • 14. JAK2 as Predictor of Therapeutic Response in Patients with Chronic Myeloid leukemia Treated with Imatinib.
    Wijaya I; Bashari MH; Reniarti L; Rahmawati A; Roesli RMA
    Dis Markers; 2024; 2024():2906566. PubMed ID: 38716474
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemia.
    Manda S; Anz BM; Benton C; Broun ER; Yimer HA; Renshaw JS; Geils G; Berdeja J; Cruz J; Melear JM; Fanning S; Fletcher L; Li Y; Duan Y; Werner ME; Potluri J; Pai MV; Donnellan WB
    Hematol Oncol; 2024 May; 42(3):e3274. PubMed ID: 38711253
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Efficacy of Episil® in patients with hematologic malignancies: a comparative study.
    Fukutani T; Yoshioka Y; Imori S; Yanagihara H; Sumi K; Myoken Y; Fujita Y; Yanamoto S
    BMC Oral Health; 2024 May; 24(1):522. PubMed ID: 38698387
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Determination of drug-related problems in the hematology service: a prospective interventional study.
    Albayrak A; Özbalcı D
    BMC Cancer; 2024 May; 24(1):552. PubMed ID: 38698336
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer (TOPAZ-1): patient-reported outcomes from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Burris HA; Okusaka T; Vogel A; Lee MA; Takahashi H; Breder V; Blanc JF; Li J; Bachini M; Żotkiewicz M; Abraham J; Patel N; Wang J; Ali M; Rokutanda N; Cohen G; Oh DY
    Lancet Oncol; 2024 May; 25(5):626-635. PubMed ID: 38697156
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Testing an Intervention to Improve Health Care Worker Well-Being During the COVID-19 Pandemic: A Cluster Randomized Clinical Trial.
    Meredith LS; Ahluwalia S; Chen PG; Dong L; Farmer CM; Bouskill KE; Dalton S; Qureshi N; Blagg T; Timmins G; Schulson LB; Huilgol SS; Han B; Williamson S; Watson P; Schnurr PP; Martineau M; Davis K; Cassells A; Tobin JN; Gidengil C
    JAMA Netw Open; 2024 Apr; 7(4):e244192. PubMed ID: 38687482
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. [Acute myeloid leukemia with central nervous system involvement successfully treated with gilteritinib].
    Koyama G; Kawaguchi T; Sato T; Hamada C; Hara S
    Rinsho Ketsueki; 2024; 65(4):231-236. PubMed ID: 38684432
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 1304.